Abbott Lodges New Zemplar Patent Suit Against Hospira

Law360, New York (February 28, 2012, 3:48 PM ET) -- Abbott Laboratories sued generic-drug maker Hospira Inc. on Monday in Delaware federal court, claiming that Hospira infringed its patent by launching plans to produce paricalcitol, which Abbott markets as the kidney disease treatment Zemplar.

Chicago-based Abbott, along with fellow plaintiff the Wisconsin Alumni Research Foundation, claims that Hospira infringed its patent when it lodged a New Drug Application with the U.S. Food and Drug Administration for approval to manufacture and sell paricalcitol injectable drug products before the expiration of Abbott's patent.

At issue is U.S. Patent...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required